Mabvax Therapeutics Holdings Incorporated (NASDAQ:MBVX) Reports Increase in Sellers; Strong Momentum for Short Players

February 15, 2018 - By Nellie Frank

 Mabvax Therapeutics Holdings Incorporated (NASDAQ:MBVX) Reports Increase in Sellers; Strong Momentum for Short Players

The stock of Mabvax Therapeutics Holdings Incorporated (NASDAQ:MBVX) registered an increase of 13.92% in short interest. MBVX’s total short interest was 629,500 shares in February as published by FINRA. Its up 13.92% from 552,600 shares, reported previously. With 371,600 shares average volume, it will take short sellers 2 days to cover their MBVX’s short positions. The short interest to Mabvax Therapeutics Holdings Incorporated’s float is 12.1%.

The stock decreased 4.77% or $0.04 during the last trading session, reaching $0.8. About 402,978 shares traded or 8.42% up from the average. MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) has declined 60.12% since February 15, 2017 and is downtrending. It has underperformed by 76.82% the S&P500.

MabVax Therapeutics Holdings, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has market cap of $18.39 million. The firm has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. It currently has negative earnings. The Company’s lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are in proof of concept Phase II multi-center clinical trials.

More notable recent MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) news were published by: which released: “MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split …” on February 15, 2018, also with their article: “MabVax Therapeutics Holdings, Inc. Provides Corporate Overview and Business …” published on October 17, 2017, published: “MabVax Therapeutics Holdings, Inc. Provides Business Strategy Update” on January 16, 2018. More interesting news about MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) were released by: and their article: “MabVax Therapeutics Holdings, Inc. (MBVX) reports 4.99% activist investor …” published on February 14, 2018 as well as‘s news article titled: “MabVax Therapeutics Holdings, Inc. Announces $1.25 Million Registered Direct …” with publication date: September 22, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.